Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 23, 2017
What is the patent landscape for Rubraca, and what generic Rubraca alternatives are available?
Rubraca is a drug marketed by Clovis Oncology Inc and is included in one NDA. There are eight patents protecting this drug.| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 1 |
| Drug Prices: | see details |
| DailyMed Link: | RUBRACA at DailyMed |
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,977,298 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | ► Subscribe | |||||||||||||
| 9,169,235 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| 7,981,889 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| 7,449,464 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| 8,912,187 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| 9,566,276 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| 7,429,578 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | ► Subscribe | |||||||||||||
| 7,662,818 | Phthalazinone derivatives | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 2534153 | ► Subscribe | |||||||||||||
| Japan | 2002534523 | ► Subscribe | |||||||||||||
| Denmark | 1684736 | ► Subscribe | |||||||||||||
| Singapore | 182533 | ► Subscribe | |||||||||||||
| San Marino | T201600462 | ► Subscribe | |||||||||||||
| Japan | 2016216507 | ► Subscribe | |||||||||||||
| Israel | 173336 | ► Subscribe | |||||||||||||
| Portugal | 1140936 | ► Subscribe | |||||||||||||
| Japan | 5580280 | ► Subscribe | |||||||||||||
| Ukraine | 94209 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2015 | Austria | ► Subscribe | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 | ||||||||||||
| 0150012 00136 | Estonia | ► Subscribe | PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014 | ||||||||||||
| 2015016,C1633724 | Lithuania | ► Subscribe | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 | ||||||||||||
| 90019-4 | Sweden | ► Subscribe | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218 | ||||||||||||
| 2015016 | Lithuania | ► Subscribe | PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216 | ||||||||||||
| 680 | Luxembourg | ► Subscribe | PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218 | ||||||||||||
| 2015 00012 | Denmark | ► Subscribe | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 | ||||||||||||
| 15/016 | Ireland | ► Subscribe | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216 | ||||||||||||
| C0022 | France | ► Subscribe | PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218 | ||||||||||||
| 500012 | Hungary | ► Subscribe | PRODUCT NAME: OLAPARIB | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 23,008 others who get our Drug Patent Expiration Alerts:
